uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations
Karolinska Inst, Karolinska Univ Hosp, Div Clin Immunol & Transfus Med, Stockholm, Sweden..
Karolinska Inst, Karolinska Univ Hosp, Div Clin Immunol & Transfus Med, Stockholm, Sweden..
Karolinska Inst, Karolinska Univ Hosp, Div Clin Immunol & Transfus Med, Stockholm, Sweden.;Beijing Genom Inst, Shenzhen, Peoples R China..
Karolinska Inst, Dept Lab Med, Div Pathol, Karolinska Univ Hosp, Stockholm, Sweden..
Show others and affiliations
2016 (English)In: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 7, no 25, p. 38180-38190Article in journal (Refereed) Published
Resource type
Text
Abstract [en]

The genetic mechanisms underlying disease progression, relapse and therapy resistance in mantle cell lymphoma (MCL) remain largely unknown. Whole-exome sequencing was performed in 27 MCL samples from 13 patients, representing the largest analyzed series of consecutive biopsies obtained at diagnosis and/or relapse for this type of lymphoma. Eighteen genes were found to be recurrently mutated in these samples, including known (ATM, MEF2B and MLL2) and novel mutation targets (S1PR1 and CARD11). CARD11, a scaffold protein required for B-cell receptor (BCR)-induced NF-kappa B activation, was subsequently screened in an additional 173 MCL samples and mutations were observed in 5.5% of cases. Based on in vitro cell line-based experiments, overexpression of CARD11 mutants were demonstrated to confer resistance to the BCR-inhibitor ibrutinib and NF-kappa B-inhibitor lenalidomide. Genetic alterations acquired in the relapse samples were found to be largely non-recurrent, in line with the branched evolutionary pattern of clonal evolution observed in most cases. In summary, this study highlights the genetic heterogeneity in MCL, in particular at relapse, and provides for the first time genetic evidence of BCR/NF-kappa B activation in a subset of MCL.

Place, publisher, year, edition, pages
2016. Vol. 7, no 25, p. 38180-38190
Keyword [en]
whole-exome sequencing, mantle cell lymphoma, relapse, CARD11, NF-kappa B inhibitor
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-299715DOI: 10.18632/oncotarget.9500ISI: 000378229100061OAI: oai:DiVA.org:uu-299715DiVA: diva2:950016
Funder
Swedish Research CouncilEU, European Research CouncilSwedish Cancer SocietySwedish Society for Medical Research (SSMF)
Available from: 2016-07-26 Created: 2016-07-26 Last updated: 2017-11-28Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records BETA

Mansouri, LarryRosenquist, Richard

Search in DiVA

By author/editor
Mansouri, LarryRosenquist, Richard
By organisation
Experimental and Clinical Oncology
In the same journal
OncoTarget
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 447 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf